Merz Pharmaceuticals GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merz Pharmaceuticals GmbH
HHS agencies look to build on COVID-19 experience by developing quicker public/private responses to pandemics and supply chain threats.
Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.
BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.
AbbVie had no presence in ophthalmic medicine other than a single indication for Humira before the Allergan merger, but now has a growing eye care portfolio, including early FDA approval of Vuity for presbyopia.
- Other Names / Subsidiaries
- BioteCon Therapeutics GmbH
- Cabochon Aesthetics, Inc.
- ON Light Sciences, Inc.
- Ulthera, Inc.
- Merz Pharmaceuticals GmbH
- Merz Pharma France
- Merz North America, Inc.
- Merz Pharma (Schweiz) Ag
- Merz Pharma GmbH